-
1by Al-Beidh, F., AMPHEUS Project, REMAP-CAP Immunoglobulin Domain UK Investigators, and Oxford COVID-19 Vaccine Trial Group, Bibi, S., Bonsall, D., Costa Clemens, S.A, Estcourt, L., Evans, A., Fish, M., Folegatti, P.M, Golubchik, T., Gordon, A.C, Harvala, H., Jay, C., Jennings, A., Laing, E., Lambe, T., MacIntyre-Cockett, G., Menon, D., Mouncey, P.R, Nguyen, D., Pollard, A.J, Ramasamy, M.N, Ratcliff, J., Roberts, D.J, Rowan, K.M, Rynne, J., Shankar-Hari, M., Simmonds, P., Williams, S.View Fulltext in Publisher
Published 2022
Article -
2by Sue Ann Costa Clemens, Pedro M. Folegatti, Katherine R. W. Emary, Lily Yin Weckx, Jeremy Ratcliff, Sagida Bibi, Ana Verena De Almeida Mendes, Eveline Pipolo Milan, Ana Pittella, Alexandre V. Schwarzbold, Eduardo Sprinz, Parvinder K. Aley, David Bonsall, Christophe Fraser, Michelle Fuskova, Sarah C. Gilbert, Daniel Jenkin, Sarah Kelly, Simon Kerridge, Teresa Lambe, Natalie G. Marchevsky, Yama F. Mujadidi, Emma Plested, Maheshi N. Ramasamy, Peter Simmonds, Tanya Golubchik, Merryn Voysey, Andrew J. Pollard, the AMPHEUS Project, Oxford COVID Vaccine Trial TeamGet full text
Published 2021-10-01
Article